CTI Life Sciences Fund related stories
All articles and analysis
Biopharma platform Domain Therapeutics nabs $42m Series AStrasbourg, France and Montreal-based biopharmaceutical company Domain Therapeutics has raised $42 million in Series A financing.
- Immunotherapeutics platform Epitopea nabs $13.6m seed deal
Epitopea, a Cambridge, UK and Montreal-based cancer immunotherapeutics company, has secured $13.6 million in seed financing.
- CTI Life Sciences Fund secures initial C$100m for third pool
Montreal-based venture capital firm CTI Life Sciences Fund has initially closed its third fund, raising C$100 million.
Phenomic AI launched with CTI Life Sciences-led seed dealToronto-based Phenomic AI, developer of a drug discovery platform, has raised US$6 million in seed financing.
Find Therapeutics launches and scores seed fundingFind Therapeutics, a Montreal-based drug discovery and development company, has been launched by Canadian venture capital firm CTI Life Sciences and its partners adMare BioInnovations, Domain Therapeutics and PeptiMimesis Pharma.
Fonds de solidarité FTQ puts $5 mln more to work in IMVFonds de solidarité FTQ has invested $5 million in IMV Inc (TSX, Nasdaq: IMV), a clinical-stage biopharmaceutical company with offices and labs in Halifax and Québec City. The investment forms part of a $29.5 million public offering announced this week. The Fonds, a Canadian growth capital provider, has to date invested $10.75 million in the company. IMV will use the offering's proceeds mainly to accelerate development of new immunotherapies for people facing cancer using its drug release platform DPX-Survivac. Founded in 2000 and led by CEO Frédéric Ors, IMV is also backed by Canadian life sciences venture capital firm CTI Life Sciences Fund.
VC-backed GLyPharma Therapeutic acquired by TherachonSwiss clinical-stage biotechnology company Therachon AG has acquired GLyPharma Therapeutic Inc, a Montréal-based developer of a drug for short bowel syndrome and other rare gastrointestinal diseases. Terms weren't disclosed. With the deal, Therachon acquires the rights to apraglutide, originally discovered by Ferring Pharmaceuticals and licensed to GLyPharma. Since its launch in 2012, GLyPharma has been backed by Canadian life sciences venture capital firm CTI Life Sciences Fund, Ferring and Fonds de solidarité FTQ. In August, Therachon raised a US$60 million financing led by Novo Holdings and joined by multiple other investors.
Otsuka completes Visterra acquisition for about $430 mlnOtsuka has closed its previously announced acquisition of Visterra, a developer of antibody-based therapies for the treatment of patients with kidney diseases and other hard-to-treat diseases, for about $430 million in cash. Visterra's backers included Polaris Partners, Flagship Pioneering, the Bill and Melinda Gates Foundation, MRL Ventures Fund, Vertex Ventures HC, Temasek Holdings, Lux Capital, Alleghany Financial Group Ventures, CTI Life Sciences Fund and Alexandria Equities.
- Otsuka to buy VC-backed Visterra for about $430 mln
Otsuka has agreed to acquire Visterra, a developer of antibody-based therapies for the treatment of patients with kidney diseases and other hard-to-treat diseases, for about $430 million in cash. The deal is expected to close in the third quarter of this year. Visterra is backed by Polaris Partners, Flagship Pioneering, the Bill and Melinda Gates Foundation, MRL Ventures Fund, Vertex Ventures HC, Serum Institute of India Private Ltd., Temasek Holdings, Omega Funds, Cycad Group, Lux Capital, Alleghany Financial Group Ventures, CTI Life Sciences Fund and Alexandria Equities.
- SutroVax reels in $85 mln Series C
Foster City, California-based SutroVax, a biopharmaceutical company, has secured $85 million in Series C financing. TPG Growth led the round with participation from other investors that included Medicxi, Foresite Capital, Abingworth, Longitude Capital, Frazier Health Care Partners, Pivotal bioVenture Partners, Roche Venture Fund and CTI Life Sciences Fund.